DE60304900D1 - Verwendung vom L-Tartrat Levalbuterolsalz in der Herstellung eines Dosierinhalators - Google Patents

Verwendung vom L-Tartrat Levalbuterolsalz in der Herstellung eines Dosierinhalators

Info

Publication number
DE60304900D1
DE60304900D1 DE60304900T DE60304900T DE60304900D1 DE 60304900 D1 DE60304900 D1 DE 60304900D1 DE 60304900 T DE60304900 T DE 60304900T DE 60304900 T DE60304900 T DE 60304900T DE 60304900 D1 DE60304900 D1 DE 60304900D1
Authority
DE
Germany
Prior art keywords
metered dose
tartrate
dose inhaler
manufacture
levalbuterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60304900T
Other languages
English (en)
Other versions
DE60304900T2 (de
Inventor
Paul Mcglynn
Roger Bakale
Craig Sturge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60304900(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of DE60304900D1 publication Critical patent/DE60304900D1/de
Application granted granted Critical
Publication of DE60304900T2 publication Critical patent/DE60304900T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0484—Alcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0488—Surfactant, e.g. for the lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
DE60304900T 2002-12-10 2003-12-08 Verwendung vom L-Tartrat Levalbuterolsalz in der Herstellung eines Dosierinhalators Expired - Lifetime DE60304900T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43219502P 2002-12-10 2002-12-10
US432195P 2002-12-10
PCT/US2003/037079 WO2004052835A1 (en) 2002-12-10 2003-12-08 Levalbuterol salt

Publications (2)

Publication Number Publication Date
DE60304900D1 true DE60304900D1 (de) 2006-06-01
DE60304900T2 DE60304900T2 (de) 2006-10-19

Family

ID=32507867

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60336089T Expired - Lifetime DE60336089D1 (de) 2002-12-10 2003-12-08 Aerosolformulierung umfassend Levalbuterol L-Tartratsalz
DE60304900T Expired - Lifetime DE60304900T2 (de) 2002-12-10 2003-12-08 Verwendung vom L-Tartrat Levalbuterolsalz in der Herstellung eines Dosierinhalators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60336089T Expired - Lifetime DE60336089D1 (de) 2002-12-10 2003-12-08 Aerosolformulierung umfassend Levalbuterol L-Tartratsalz

Country Status (19)

Country Link
US (8) US7256310B2 (de)
EP (3) EP2292584B1 (de)
JP (1) JP4570960B2 (de)
KR (3) KR20050088307A (de)
AT (2) ATE324364T1 (de)
AU (1) AU2003295695B2 (de)
CA (1) CA2507572C (de)
CY (2) CY1106315T1 (de)
DE (2) DE60336089D1 (de)
DK (3) DK2292584T3 (de)
ES (3) ES2361172T5 (de)
IL (2) IL168739A (de)
MX (1) MXPA05006087A (de)
NO (1) NO331649B1 (de)
NZ (1) NZ541168A (de)
PL (1) PL212725B1 (de)
PT (3) PT2292584T (de)
SI (2) SI1572622T1 (de)
WO (1) WO2004052835A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6466862B1 (en) * 1999-04-19 2002-10-15 Bruce DeKock System for providing traffic information
WO2006027595A1 (en) * 2004-09-09 2006-03-16 Cipla Limited Pharmaceutical composition comprising an isomer of a betamimetic agent and an anti-cholinergic agent
AU2005315337B2 (en) 2004-12-17 2012-07-05 Cipla Limited Pharmaceutical compounds and compositions
US7579505B2 (en) 2004-12-17 2009-08-25 Cipla Limited Crystalline levosalbutamol sulphate and polymorphic forms thereof
US8542097B2 (en) 2011-04-13 2013-09-24 Jingle Technologies Llc Systems and methods for transmitting information, alerts, and/or comments to participants based on location information
EP3042892A1 (de) 2015-01-09 2016-07-13 Deva Holding Anonim Sirketi Amorphisierung von Levosalbutamoltartrat
CN106727318A (zh) * 2016-12-22 2017-05-31 山东京卫制药有限公司 一种气雾剂及其制备方法
US20210290568A1 (en) * 2020-03-19 2021-09-23 Cai Gu Huang Inhalable formulation of a solution containing levalbuterol tartrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5345980A (en) 1989-09-21 1994-09-13 Glaxo Group Limited Method and apparatus an aerosol container
US5362755A (en) 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5255183A (en) * 1990-05-29 1993-10-19 Interactive Voice Data System Inc. Telephone-based personnel tracking system
CA2111003A1 (en) 1991-06-10 1992-12-23 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
ES2099415T3 (es) 1991-12-18 1997-05-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
US5399765A (en) 1994-05-23 1995-03-21 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
TR199701167T1 (xx) * 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Albuterol i�in �l��lm�� doz inhaleri.
US5603918A (en) 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
ATE283033T1 (de) * 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
CN1173929C (zh) 1999-10-19 2004-11-03 中国科学院成都有机化学研究所 光学纯肾上腺素类β-激动剂的组合拆分制备法
US6451289B2 (en) 2000-03-24 2002-09-17 Sepracor Inc. Albuterol formulations
GB0030171D0 (en) 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
ATE375142T1 (de) * 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
DE10120531A1 (de) * 2001-04-26 2002-10-31 Basf Ag Neue Reaktivfarbstoffe und deren Verwendung zum Färben von Substraten, welche nucleophile Gruppen enthalten
CN1206205C (zh) * 2001-04-26 2005-06-15 中国科学院成都有机化学研究所 R－沙丁胺醇酒石酸盐的制备方法

Also Published As

Publication number Publication date
PL212725B1 (pl) 2012-11-30
DK1671942T3 (da) 2011-04-26
EP1572622A1 (de) 2005-09-14
IL168739A (en) 2011-06-30
DK1572622T3 (da) 2006-08-28
ATE324364T1 (de) 2006-05-15
CA2507572C (en) 2011-04-19
US20160368858A1 (en) 2016-12-22
US20080119564A1 (en) 2008-05-22
US20130236515A1 (en) 2013-09-12
ES2361172T3 (es) 2011-06-14
US20040115136A1 (en) 2004-06-17
CA2507572A1 (en) 2004-06-24
SI1671942T2 (sl) 2014-10-30
US20130028845A1 (en) 2013-01-31
EP2292584B1 (de) 2017-03-01
NO20053339L (no) 2005-09-07
PL377336A1 (pl) 2006-01-23
KR20100080865A (ko) 2010-07-12
DK1671942T4 (da) 2014-09-22
DE60304900T2 (de) 2006-10-19
US20150071969A1 (en) 2015-03-12
US8765153B2 (en) 2014-07-01
JP4570960B2 (ja) 2010-10-27
ATE498604T1 (de) 2011-03-15
NO20053339D0 (no) 2005-07-08
MXPA05006087A (es) 2005-09-30
KR101166955B1 (ko) 2012-07-19
AU2003295695B2 (en) 2009-08-20
DE60336089D1 (de) 2011-03-31
PT1671942E (pt) 2011-05-11
EP2292584A1 (de) 2011-03-09
US20100272654A1 (en) 2010-10-28
EP1671942B2 (de) 2014-07-23
KR20050088307A (ko) 2005-09-05
WO2004052835A1 (en) 2004-06-24
NO331649B1 (no) 2012-02-13
US7256310B2 (en) 2007-08-14
US20180222845A1 (en) 2018-08-09
IL212369A0 (en) 2011-06-30
AU2003295695A1 (en) 2004-06-30
IL212369A (en) 2013-08-29
EP1671942A1 (de) 2006-06-21
NZ541168A (en) 2008-10-31
ES2361172T5 (es) 2014-09-22
PT2292584T (pt) 2017-06-12
PT1572622E (pt) 2006-08-31
EP1572622B1 (de) 2006-04-26
ES2626648T3 (es) 2017-07-25
SI1671942T1 (sl) 2011-04-29
SI1572622T1 (sl) 2006-10-31
JP2006509802A (ja) 2006-03-23
EP1671942B1 (de) 2011-02-16
DK2292584T3 (en) 2017-05-01
CY1106315T1 (el) 2011-10-12
KR20080103614A (ko) 2008-11-27
CY1111330T1 (el) 2015-08-05
ES2263051T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
DE602005004808D1 (de) Körperpflegezusammensetzungen mit salzen von mit dihydroxypropyltri(c1-c3alkyl) ammonium monosubstituierten polyolen
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
DE502006002956D1 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
MX2007008928A (es) Aminoacidos n-halogenados y aminoacidos n, n-dihalogenados en combinacion con acidos hipohalosos.
NO20053339D0 (no) Levalbuterolsalt.
TW200732303A (en) Novel fused pyrrole derivatives
DE112007001669A5 (de) Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
SE0203497L (sv) Anordning avsedd att ingå i framställning av kolfiberförstärkt tandprotes
DE60325551D1 (de) Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
DE602005000442D1 (de) Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie
ATE491443T1 (de) Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen
ATE540922T1 (de) Zur behandlung von erkrankungen, die auf eine modulation des dopamin-d3-rezeptors ansprechen, geeignete aminoethylaromatische verbindungen
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες
TW200502202A (en) Therapeutic agents
DK1755583T3 (da) Anvendelse af neboglamin til behandling af skizofreni
ATE419853T1 (de) Thiazolopyrimidine zur verwendung in der therapie
UA35751U (ru) Применение препарата "кристалл-900" в виде дезинфицирующего средства в рыбоводстве
AU2005907076A0 (en) A stand-alone mechanical counter that fits onto existing pressurised Metered Dose Inhalers(pMDIs) used to deliver medication to the lungs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition